Purpose

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Category

IRB Number
20170525HU
NCT Number
NCT02465060
Open to Enrollment
Yes
Sponsor
National Cancer Institute (NCI) -



Study Contact

Principal Investigator
Virginia Kaklamani

Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu

Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu

Virginia Kaklamani
(210) 450-3838
kaklamani@uthscsa.edu

Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu

Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu

Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu

Regulatory Staff
regaffstaff@uthscsa.edu

Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu

Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu



Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Exclusion Criteria


      Study Design

      Phase
      Phase 2
      Study Type
      Interventional
      Allocation
      Non-Randomized
      Intervention Model
      Parallel Assignment
      Primary Purpose
      Treatment
      Masking
      None (Open Label)
      Condition
    1. Advanced Malignant Solid Neoplasm
    2. Bladder Carcinoma
    3. Breast Carcinoma
    4. Cervical Carcinoma
    5. Colon Carcinoma
    6. Colorectal Carcinoma
    7. Endometrial Carcinoma
    8. Esophageal Carcinoma
    9. Gastric Carcinoma
    10. Glioma
    11. Head and Neck Carcinoma
    12. Kidney Carcinoma
    13. Liver and Intrahepatic Bile Duct Carcinoma
    14. Lung Carcinoma
    15. Lymphoma
    16. Malignant Uterine Neoplasm
    17. Melanoma
    18. Ovarian Carcinoma
    19. Pancreatic Carcinoma
    20. Plasma Cell Myeloma
    21. Prostate Carcinoma
    22. Rectal Carcinoma
    23. Recurrent Bladder Carcinoma
    24. Recurrent Breast Carcinoma
    25. Recurrent Cervical Carcinoma
    26. Recurrent Colon Carcinoma
    27. Recurrent Colorectal Carcinoma
    28. Recurrent Esophageal Carcinoma
    29. Recurrent Gastric Carcinoma
    30. Recurrent Glioma
    31. Recurrent Head and Neck Carcinoma
    32. Recurrent Liver Carcinoma
    33. Recurrent Lung Carcinoma
    34. Recurrent Lymphoma
    35. Recurrent Malignant Solid Neoplasm
    36. Recurrent Melanoma
    37. Recurrent Ovarian Carcinoma
    38. Recurrent Pancreatic Carcinoma
    39. Recurrent Plasma Cell Myeloma
    40. Recurrent Prostate Carcinoma
    41. Recurrent Rectal Carcinoma
    42. Recurrent Skin Carcinoma
    43. Recurrent Thyroid Gland Carcinoma
    44. Recurrent Uterine Corpus Cancer
    45. Refractory Lymphoma
    46. Refractory Malignant Solid Neoplasm
    47. Refractory Plasma Cell Myeloma
    48. Skin Carcinoma
    49. Thyroid Gland Carcinoma
    50. Uterine Corpus Cancer
    51. Arm Groups

      ArmDescriptionIntervention
      Experimental

      Subprotocol A (EGFR activating mutation)

      Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    52. Drug: Afatinib

      Given PO

      Other names:

      • BIBW 2992
      • BIBW2992

    53. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    54. Drug: Afatinib Dimaleate

      Given PO

      Other names:

      • (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)
      • BIBW 2992MA2
      • BIBW2992 MA2

    55. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    56. Experimental

      Subprotocol C1 (MET amplification)

      Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    57. Drug: Crizotinib

      Given PO

      Other names:

      • MET Tyrosine Kinase Inhibitor PF-02341066
      • PF-02341066
      • PF-2341066
      • Xalkori

    58. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    59. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    60. Experimental

      Subprotocol E (EGFR T790M or rare activating mutation)

      Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    61. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    62. Drug: Osimertinib

      Given PO

      Other names:

      • AZD-9291
      • AZD9291
      • Mereletinib
      • Tagrisso

    63. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    64. Experimental

      Subprotocol G (ROS1 translocation or inversion)

      Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    65. Drug: Crizotinib

      Given PO

      Other names:

      • MET Tyrosine Kinase Inhibitor PF-02341066
      • PF-02341066
      • PF-2341066
      • Xalkori

    66. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    67. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    68. Experimental

      Subprotocol I (PIK3CA mutation)

      Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    69. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    70. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    71. Drug: Taselisib

      Given PO

      Other names:

      • GDC-0032
      • RO5537381

    72. Experimental

      Subprotocol M (TSC1 or TSC2 mutation)

      Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
    73. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    74. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    75. Drug: Sapanisertib

      Given PO

      Other names:

      • INK-128
      • INK128
      • MLN-0128
      • MLN0128
      • TAK-228

    76. Experimental

      Subprotocol P (PTEN loss)

      Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    77. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    78. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    79. Drug: PI3K-beta Inhibitor GSK2636771

      Given PO

      Other names:

      • GSK2636771

    80. Experimental

      Subprotocol R (BRAF fusion or BRAF non-V600 mutation)

      Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    81. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    82. Drug: Trametinib

      Given PO

      Other names:

      • GSK1120212
      • JTP-74057
      • MEK Inhibitor GSK1120212

    83. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    84. Experimental

      Subprotocol S2 (GNAQ or GNA11 mutation)

      Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    85. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    86. Drug: Trametinib

      Given PO

      Other names:

      • GSK1120212
      • JTP-74057
      • MEK Inhibitor GSK1120212

    87. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    88. Experimental

      Subprotocol U (NF2 inactivating mutation)

      Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    89. Drug: Defactinib Hydrochloride

      Given PO

      Other names:

      • PF-04554878
      • VS-6063

    90. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    91. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    92. Drug: Defactinib

      Given PO

    93. Experimental

      Subprotocol W (FGFR pathway aberrations)

      Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    94. Drug: FGFR Inhibitor AZD4547

      Given PO

      Other names:

      • AZD4547

    95. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    96. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    97. Experimental

      Subprotocol Y (Akt mutation)

      Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    98. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    99. Drug: Capivasertib

      Given PO

      Other names:

      • AZD5363

    100. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    101. Experimental

      Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)

      Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    102. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    103. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    104. Drug: Palbociclib

      Given PO

      Other names:

      • 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
      • Ibrance
      • PD 0332991
      • PD 332991
      • PD 991
      • PD-0332991

    105. Experimental

      Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)

      Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    106. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    107. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    108. Biological: Nivolumab

      Given IV

      Other names:

      • BMS-936558
      • MDX-1106
      • NIVO
      • ONO-4538
      • Opdivo

    109. Experimental

      Subprotocol Z1F (PIK3CA mutation)

      Patients with PIK3CA mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    110. Drug: Copanlisib

      Given IV

      Other names:

      • BAY 80-6946
      • PI3K Inhibitor BAY 80-6946

    111. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    112. Drug: Copanlisib Hydrochloride

      Given IV

      Other names:

      • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
      • Aliqopa
      • BAY 80-6946 Dihydrochloride
      • BAY-80

    113. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    114. Experimental

      Subprotocol Z1H (PTEN mutation)

      Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    115. Drug: Copanlisib

      Given IV

      Other names:

      • BAY 80-6946
      • PI3K Inhibitor BAY 80-6946

    116. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    117. Drug: Copanlisib Hydrochloride

      Given IV

      Other names:

      • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
      • Aliqopa
      • BAY 80-6946 Dihydrochloride
      • BAY-80

    118. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    119. Experimental

      Subprotocol Z1K (AKT mutation)

      Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    120. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    121. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    122. Drug: Ipatasertib

      Given PO

      Other names:

      • GDC-0068
      • RG-7440

    123. Experimental

      Subprotocol Z1M (LAG-3 expression >= 1%)

      Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    124. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    125. Biological: Relatlimab

      Given IV

      Other names:

      • BMS-986016
      • BMS986016
      • Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer

    126. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    127. Biological: Nivolumab

      Given IV

      Other names:

      • BMS-936558
      • MDX-1106
      • NIVO
      • ONO-4538
      • Opdivo

    128. Experimental

      Subprotocol K1 (FGFR amplification)

      Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    129. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    130. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    131. Drug: Erdafitinib

      Given PO

      Other names:

      • Balversa
      • JNJ-42756493

    132. Experimental

      Subprotocol L (mTOR mutation)

      Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
    133. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    134. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    135. Drug: Sapanisertib

      Given PO

      Other names:

      • INK-128
      • INK128
      • MLN-0128
      • MLN0128
      • TAK-228

    136. Experimental

      Subprotocol N (PTEN mutation or deletion and PTEN expression)

      Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    137. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    138. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    139. Drug: PI3K-beta Inhibitor GSK2636771

      Given PO

      Other names:

      • GSK2636771

    140. Experimental

      Subprotocol Q (HER2 amplification)

      Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    141. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    142. Biological: Trastuzumab Emtansine

      Given IV

      Other names:

      • Ado Trastuzumab Emtansine
      • ADO-Trastuzumab Emtansine
      • Kadcyla
      • PRO132365
      • RO5304020
      • T-DM1
      • Trastuzumab-DM1
      • Trastuzumab-MCC-DM1
      • Trastuzumab-MCC-DM1 Antibody-Drug

    143. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    144. Biological: Trastuzumab

      Given IV

      Other names:

      • ABP 980
      • ALT02
      • Anti-c-ERB-2
      • Anti-c-erbB2 Monoclonal Antibody
      • Anti-ERB-2
      • Anti-erbB-2
      • Anti-erbB2 Monoclonal Antibody
      • Anti-HER2/c-erbB2 Monoclonal Antibody
      • Anti

    145. Experimental

      Subprotocol S1 (NF1 mutation)

      Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    146. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    147. Drug: Trametinib

      Given PO

      Other names:

      • GSK1120212
      • JTP-74057
      • MEK Inhibitor GSK1120212

    148. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    149. Experimental

      Subprotocol T (SMO or PTCH1 mutation)

      Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    150. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    151. Drug: Vismodegib

      Given PO

      Other names:

      • Erivedge
      • GDC-0449
      • Hedgehog Antagonist GDC-0449

    152. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    153. Experimental

      Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)

      Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
    154. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    155. Drug: Sunitinib Malate

      Given PO

      Other names:

      • SU011248
      • SU11248
      • sunitinib
      • Sutent

    156. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    157. Experimental

      Subprotocol X (DDR2 S768R, I638F, or L239R mutation)

      Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    158. Drug: Dasatinib

      Given PO

      Other names:

      • BMS-354825
      • Dasatinib Hydrate
      • Dasatinib Monohydrate
      • Sprycel

    159. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    160. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    161. Experimental

      Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)

      Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    162. Drug: Binimetinib

      Given PO

      Other names:

      • ARRY-162
      • ARRY-438162
      • MEK162
      • Mektovi

    163. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    164. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    165. Experimental

      Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)

      Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    166. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    167. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    168. Drug: Palbociclib

      Given PO

      Other names:

      • 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
      • Ibrance
      • PD 0332991
      • PD 332991
      • PD 991
      • PD-0332991

    169. Experimental

      Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)

      Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    170. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    171. Drug: Larotrectinib Sulfate

      Given PO

      Other names:

      • ARRY 470 Sulfate
      • LOXO 101 Sulfate
      • LOXO-101 Sulfate
      • Vitrakvi

    172. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    173. Drug: Larotrectinib

      Given PO

      Other names:

      • ARRY 470
      • LOXO 101
      • LOXO-101

    174. Experimental

      Subprotocol Z1G (PTEN loss)

      Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    175. Drug: Copanlisib

      Given IV

      Other names:

      • BAY 80-6946
      • PI3K Inhibitor BAY 80-6946

    176. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    177. Drug: Copanlisib Hydrochloride

      Given IV

      Other names:

      • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
      • Aliqopa
      • BAY 80-6946 Dihydrochloride
      • BAY-80

    178. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    179. Experimental

      Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)

      Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    180. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    181. Drug: Adavosertib

      Given PO

      Other names:

      • AZD-1775
      • AZD1775
      • MK-1775
      • MK1775

    182. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    183. Experimental

      Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)

      Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    184. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    185. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    186. Drug: Ulixertinib

      Give PO

      Other names:

      • BVD-523
      • VRT752271

    187. Experimental

      Subprotocol B (HER2 activating mutation)

      Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    188. Drug: Afatinib

      Given PO

      Other names:

      • BIBW 2992
      • BIBW2992

    189. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    190. Drug: Afatinib Dimaleate

      Given PO

      Other names:

      • (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)
      • BIBW 2992MA2
      • BIBW2992 MA2

    191. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    192. Experimental

      Subprotocol C2 (MET exon 14 deletion/mutation)

      Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    193. Drug: Crizotinib

      Given PO

      Other names:

      • MET Tyrosine Kinase Inhibitor PF-02341066
      • PF-02341066
      • PF-2341066
      • Xalkori

    194. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    195. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    196. Experimental

      Subprotocol F (ALK translocation)

      Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    197. Drug: Crizotinib

      Given PO

      Other names:

      • MET Tyrosine Kinase Inhibitor PF-02341066
      • PF-02341066
      • PF-2341066
      • Xalkori

    198. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    199. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    200. Experimental

      Subprotocol H (BRAF V600E/R/K/D mutation)

      Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    201. Drug: Dabrafenib

      Given PO

      Other names:

      • BRAF Inhibitor GSK2118436
      • GSK-2118436
      • GSK-2118436A
      • GSK2118436

    202. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    203. Drug: Trametinib

      Given PO

      Other names:

      • GSK1120212
      • JTP-74057
      • MEK Inhibitor GSK1120212

    204. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    205. Drug: Dabrafenib Mesylate

      Given PO

      Other names:

      • Dabrafenib Methanesulfonate
      • GSK2118436 Methane Sulfonate Salt
      • GSK2118436B
      • Tafinlar

    206. Experimental

      Subprotocol J (HER2 amplification >= 7 copy numbers)

      Patients with HER2 amplification >= 7 copy numbers receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
    207. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    208. Biological: Pertuzumab

      Given IV

      Other names:

      • 2C4
      • 2C4 Antibody
      • HS627
      • MoAb 2C4
      • Monoclonal Antibody 2C4
      • Omnitarg
      • Perjeta
      • Pertuzumab Biosimilar HS627
      • rhuMAb2C4
      • RO4368451

    209. Biological: Trastuzumab Emtansine

      Given IV

      Other names:

      • Ado Trastuzumab Emtansine
      • ADO-Trastuzumab Emtansine
      • Kadcyla
      • PRO132365
      • RO5304020
      • T-DM1
      • Trastuzumab-DM1
      • Trastuzumab-MCC-DM1
      • Trastuzumab-MCC-DM1 Antibody-Drug

    210. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    211. Biological: Trastuzumab

      Given IV

      Other names:

      • ABP 980
      • ALT02
      • Anti-c-ERB-2
      • Anti-c-erbB2 Monoclonal Antibody
      • Anti-ERB-2
      • Anti-erbB-2
      • Anti-erbB2 Monoclonal Antibody
      • Anti-HER2/c-erbB2 Monoclonal Antibody
      • Anti

    212. Experimental

      Subprotocol K2 (FGFR mutation or fusion)

      Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    213. Other: Laboratory Biomarker Analysis

      Undergo molecular analysis

    214. Other: Cytology Specimen Collection Procedure

      Optional correlative studies

      Other names:

      • Cytologic Sampling

    215. Drug: Erdafitinib

      Given PO

      Other names:

      • Balversa
      • JNJ-42756493